36411479|t|Effect of esketamine vs dexmedetomidine adjunct to propofol sedation for pediatric 3Tesla magnetic resonance imaging: a randomized, double-blind, controlled trial.
36411479|a|BACKGROUND: Adequate sedation is essential for pediatric patients undergoing 3Tesla (T) magnetic resonance imaging (MRI). Using propofol alone is associated with patient arousing and adverse airway events. This study aimed to assess esketamine vs dexmedetomidine adjunct to propofol sedation for pediatric 3 T MRI. METHODS: In this randomized, double-blind, controlled trial, 114 pediatric patients aged between 6 months and 8 years were randomly assigned, in a 1:1 ratio, to the esketamine-propofol group or the dexmedetomidine-propofol group. Sedation was provided with esketamine or dexmedetomidine in combination with propofol titration. The primary outcome was the total dose of propofol. Secondary outcomes included propofol infusion dose, adverse events, time to emergence from sedation, and time to discharge from recovery room. RESULTS: A total of 111 patients completed this study (56 in the esketamine-propofol group and 55 in the dexmedetomidine-propofol group). All MRI procedures were successfully performed under sedation. The total median (IQR) dose of propofol was significantly lower in the esketamine-propofol group (159.8 [121.7, 245.2] mug/kg/min) than that in the dexmedetomidine-propofol group (219.3 [188.6, 314.8] mug/kg/min) (difference in medians [95% CI] =  - 66.9 [- 87.8 to - 43.0] mug/kg/min, P < 0.0001). The use of esketamine resulted in a lower dose of propofol for titration (difference in medians [95% CI] =  - 64.3 [- 75.9 to - 51.9] mug/kg/min), a shorter time to emergence (difference in means [95% CI] =  - 9.4 [- 11.4 to - 7.4] min), and a reduced time to recovery room discharge (difference in means [95% CI] =  - 10.1 [- 12.1 to - 8.2] min). In the dexmedetomidine-propofol group, 2 patients experienced upper airway obstruction and 6 patients had bradycardia. No episodes of oxygen desaturation or other adverse events were observed. CONCLUSIONS: Although both regimens provided effective sedation for pediatric 3 T MRI, the esketamine-propofol sedation reduced propofol requirement and facilitated recovery, without detection of increased adverse effects in the studied population. Trial registration Chinese Clinical Trial Registry (identifier: ChiCTR2100048477).
36411479	10	20	esketamine	Chemical	MESH:C000629870
36411479	24	39	dexmedetomidine	Chemical	MESH:D020927
36411479	51	59	propofol	Chemical	MESH:D015742
36411479	221	229	patients	Species	9606
36411479	292	300	propofol	Chemical	MESH:D015742
36411479	326	333	patient	Species	9606
36411479	397	407	esketamine	Chemical	MESH:C000629870
36411479	411	426	dexmedetomidine	Chemical	MESH:D020927
36411479	438	446	propofol	Chemical	MESH:D015742
36411479	554	562	patients	Species	9606
36411479	644	654	esketamine	Chemical	MESH:C000629870
36411479	655	663	propofol	Chemical	MESH:D015742
36411479	677	692	dexmedetomidine	Chemical	MESH:D020927
36411479	693	701	propofol	Chemical	MESH:D015742
36411479	736	746	esketamine	Chemical	MESH:C000629870
36411479	750	765	dexmedetomidine	Chemical	MESH:D020927
36411479	786	794	propofol	Chemical	MESH:D015742
36411479	848	856	propofol	Chemical	MESH:D015742
36411479	886	894	propofol	Chemical	MESH:D015742
36411479	1025	1033	patients	Species	9606
36411479	1066	1076	esketamine	Chemical	MESH:C000629870
36411479	1077	1085	propofol	Chemical	MESH:D015742
36411479	1106	1121	dexmedetomidine	Chemical	MESH:D020927
36411479	1122	1130	propofol	Chemical	MESH:D015742
36411479	1233	1241	propofol	Chemical	MESH:D015742
36411479	1273	1283	esketamine	Chemical	MESH:C000629870
36411479	1284	1292	propofol	Chemical	MESH:D015742
36411479	1350	1365	dexmedetomidine	Chemical	MESH:D020927
36411479	1366	1374	propofol	Chemical	MESH:D015742
36411479	1512	1522	esketamine	Chemical	MESH:C000629870
36411479	1551	1559	propofol	Chemical	MESH:D015742
36411479	1856	1871	dexmedetomidine	Chemical	MESH:D020927
36411479	1872	1880	propofol	Chemical	MESH:D015742
36411479	1890	1898	patients	Species	9606
36411479	1917	1935	airway obstruction	Disease	MESH:D000402
36411479	1942	1950	patients	Species	9606
36411479	1955	1966	bradycardia	Disease	MESH:D001919
36411479	1983	2002	oxygen desaturation	Disease	MESH:D000860
36411479	2133	2143	esketamine	Chemical	MESH:C000629870
36411479	2144	2152	propofol	Chemical	MESH:D015742
36411479	2170	2178	propofol	Chemical	MESH:D015742
36411479	Positive_Correlation	MESH:D020927	MESH:D001919
36411479	Cotreatment	MESH:D015742	MESH:D020927
36411479	Positive_Correlation	MESH:C000629870	MESH:D001919
36411479	Comparison	MESH:C000629870	MESH:D020927
36411479	Positive_Correlation	MESH:D015742	MESH:D001919
36411479	Negative_Correlation	MESH:D015742	MESH:D000860
36411479	Negative_Correlation	MESH:C000629870	MESH:D015742

